Monitor Corporation Targets Japan's Medical Market

Korean medical AI technology is bringing innovation to the Japanese medical field. Monitor Corporation, a leader in the lung cancer diagnosis sector, has successfully launched its AI solution 'MonCAD CTLN' into the Japanese market by partnering with Doctonet, Japan's largest telemedicine company. Established in 2018 by professors from Seoul National University Bundang Hospital, Monitor Corporation has already established an unrivaled position in Korea with its chest CT-based lung cancer diagnosis solution. As the only Class III innovative medical device 'LUCS' in Korea, it has proven its value in over 100 medical institutions, demonstrating the power of 'K-Medical AI'. This technology, branded as 'MonCAD' in the global market, is now heading to Japan. Doctonet, a key partner in the Japanese market, is the overwhelming No. 1 company, collaborating with over 1,300 medical institutions and processing more than 3 million telemedicine cases annually. Through close collaboration with them, 'MonCAD CTLN' has obtained manufacturing and sales approval within Japan and has officially begun its service. Lee Kyung-joon, CEO of Monitor Corporation, pointed out that despite lung cancer being the leading cause of death for men and the second for women in Japan, a shortage of expert radiologists means that a single medical professional interprets 3 to 4 times more images compared to the US. This leads to an explosive demand for AI solutions. This entry into Japan marks a significant global expansion following Monitor Corporation's successful Series B investment round of 7 billion KRW. Japanese medical institutions currently using Doctonet's services can now immediately utilize 'MonCAD CTLN' without any separate procedures, which is expected to dramatically increase the diagnostic accuracy and efficiency of medical professionals. It remains to be seen whether this innovative technology, proven in Korea, will create a successful best practice in the Japanese market and emerge as a leader in the global medical AI market.